Story perspectives

Breakthrough Target Identified for Barth Syndrome Treatment

9/4/2025

50 4

Summary

Story summary

Researchers at SickKids identified ABHD18 as a potential target for Barth syndrome, affecting approximately 500 people worldwide.
Inhibiting ABHD18 improves mitochondrial function and cardiac health by restoring lipid balance disrupted by TAFAZZIN mutations.
The study presents ABD646, a compound that may reduce harmful lipid accumulation and enhance heart function.
Further clinical trials are necessary to develop effective treatments based on these findings.

1 of 1

Story summary

Researchers at SickKids identified ABHD18 as a potential target for Barth syndrome, affecting approximately 500 people worldwide.
Inhibiting ABHD18 improves mitochondrial function and cardiac health by restoring lipid balance disrupted by TAFAZZIN mutations.
The study presents ABD646, a compound that may reduce harmful lipid accumulation and enhance heart function.
Further clinical trials are necessary to develop effective treatments based on these findings.